A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

Condition:   Idiopathic Inflammatory Myositis Interventions:   Drug: Daxdilimab;   Drug: Placebo Sponsor:   Horizon Therapeutics Ireland DAC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials